HKSE · 6855.HK
Ascentage Pharma Group International
HK$28.02-HK$0.20 (-0.71%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
Loading market information…
HKSE · 2256.HK · HKD
Stock price, earnings
Quote as of Oct 30, 2026, 03:58 AM UTC. Cached market data; not a live quote.
One-year closing-price history · HKD. Historical prices are not a forecast.
Abbisko Cayman Limited’s quoted price sits in the lower half of its reported 52-week range, 57.59% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Abbisko Cayman Limited’s next earnings report is currently expected on Mar 18, 2027, with estimated earnings per share of -HK$0.51. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Abbisko Cayman Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
Latest available per-share figures in HKD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:29 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2024 |
|---|
| Jun 18, 2024 |
| HK$0.17 |
| HK$269.00M |
| Q4 2023 | Mar 12, 2024 | -HK$0.37+34.61% vs estimate | HK$0.00 |
|---|
| Q2 2023 | Aug 16, 2023 | -HK$0.18+69.06% vs estimate | HK$10.88M |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
HK$28.02-HK$0.20 (-0.71%)
Ascentage Pharma Group International’s quoted price sits in the lower half of its reported 52-week range, 59.6% below the high.
HK$9.91+HK$0.06 (+0.61%)
HBM Holdings Limited’s quoted price sits in the lower half of its reported 52-week range, 41.97% below the high.
HK$5.05+HK$0.31 (+6.55%)
CStone Pharmaceuticals’s quoted price sits in the lower half of its reported 52-week range, 51.54% below the high.
HK$6.34-HK$0.15 (-2.31%)
Alphamab Oncology’s quoted price sits in the lower half of its reported 52-week range, 48.03% below the high.
HK$3.21+HK$0.14 (+4.57%)
Lepu Biopharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 53.42% below the high.
HK$4.68+HK$0.05 (+0.97%)
Jacobio Pharmaceuticals Group Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 49.68% below the high.
HK$26.10-HK$0.34 (-1.29%)
Hanx Biopharmaceuticals (Wuhan) Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 22.78% below the high.
HK$9.14-HK$0.46 (-4.79%)
Impact Therap-b’s quoted price sits in the lower half of its reported 52-week range, 80.96% below the high.
